Projected Earnings Date: 2025-11-09    (Delayed quote data   2025-09-12)
Last
 46.99
Change
 ⇑ +0.79   (+1.71%)
Volume
  579,311
Open
 46.19
High
 47.35
Low
 45.84
8EMA (Daily)
 44.42
40EMA (Daily)
 42.97
50EMA (Daily)
 42.67
STO (Daily)
 84.839
MACD Hist (Daily)
 0.983
8EMA (Weekly)
 43.749
40EMA (Weekly)
 40.00
50EMA (Weekly)
 39.49
STO (Weekly)
 64.654
MACD Hist (Weekly)
 0.488
Kymera Therapeutics Inc is a biotechnology company pioneering a transformative new approach to treating previously untreatable diseases. The company is advancing the field of targeted protein degradation, accessing the body's innate protein recycling machinery to degrade dysregulated, disease-causing proteins. Kymera's Pegasus targeted protein degradation platform harnesses the body's natural protein recycling machinery to degrade disease-causing proteins, with a focus on un-drugged nodes in validated pathways currently inaccessible with conventional therapeutics. It is accelerating drug discovery with an unmatched ability to target and degrade intractable proteins and advance new treatment options for patients.
optionchance optionchance
Home | Chart and Research | Education | About Us  

Disclaimer: All information provided is for informational purposes only and not intended for trading purposes or advice. The quotes and charts are not real time and have delays of at least 20 minutes. Data accuracy cannot be guaranteed as errors will occur. Please do not rely on the above information to make your stock/option trades. Neither OptionChance.com nor any of independent data providers is liable for any informational errors, incompleteness, or delays, or for any actions taken in reliance on information contained herein.

Questions or Comments: support@optionchance.com
Copyright © 2025 OptionChance.com